Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.48 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | WDR5 | P61964 | 3/20 | 0.42 |
| ▸ | ATP4A | P20648 | 2/20 | 0.42 |
| ▸ | ATP4B | P51164 | 2/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | BRS3 | P32247 | 2/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.41 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.41 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.41 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29546790 | 1.00 | AGXT (0.64) | AGXTHSP90AA1TRAP1HSP90AB1HSP90B1 | |
| Hydrochloric Acid SCHEMBL29385728 | 0.98 | AGXT (0.62) | AGXTHSP90AA1TRAP1HSP90AB1HSP90B1 | |
| Hydrochloric Acid SCHEMBL311423 | 0.98 | AGXT (0.62) | AGXTHSP90AA1TRAP1HSP90AB1HSP90B1 | |
| SCHEMBL29892728 | 0.98 | AGXT (0.62) | AGXTHSP90AA1TRAP1HSP90AB1HSP90B1 | |
| Hydrochloric Acid SCHEMBL8063817 | 0.92 | AGXT (0.55) | AGXTHSP90AA1TRAP1HSP90AB1HSP90B1 | |
| SCHEMBL3801066 | 0.90 | AGXT (0.53) | AGXTHSP90AA1TRAP1HSP90AB1HSP90B1 | |
| SCHEMBL2629580 | 0.85 | AGXT (0.46) | AGXTHSP90AA1TRAP1HSP90AB1HSP90B1 | |
| SCHEMBL27278545 | 0.83 | AGXT (0.45) | AGXTHSP90AA1TRAP1HSP90AB1HSP90B1 | |
| SCHEMBL2629579 | 0.83 | AGXT (0.49) | AGXTHSP90AA1TRAP1HSP90AB1HSP90B1 | |
| Hydrochloric Acid SCHEMBL2111386 | 0.83 | AGXT (0.45) | AGXTHSP90AA1TRAP1HSP90AB1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114184699-B | Method for determining potential genotoxic impurities in esomeprazole sodium by liquid chromatography-mass spectrometry | 北京悦康科创医药科技股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-114805193-B | Preparation method of omeprazole intermediate | 南京红太阳医药研究院有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-115785067-A | Preparation method of impurity compound of esomeprazole thioether | 北京京卫燕康药物研究所有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-112229920-B | Method for detecting potential genotoxic impurities of esomeprazole sodium | 海南中玉药业有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-110317164-B | Preparation method of omeprazole intermediate | 抚州三和医药化工有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114805193-A | Preparation method of omeprazole intermediate | 南京红太阳医药研究院有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-110317164-A | A kind of preparation method of intermediate of omeprazole | 抚州三和医药化工有限公司 | 2019-10-11 | — | — | CN | claimed |
| CN-104803978-B | A kind of preparation method of esomeprazole magnesium | 艾美科健（中国）生物医药有限公司 | 2019-06-18 | — | — | CN | claimed |
| CN-103936715-B | The process for purification of a kind of Esomeprazole sodium and synthetic method | 哈尔滨珍宝制药有限公司 | 2016-08-24 | — | — | CN | claimed |
| CN-103694223-B | A kind of one kettle way prepares the method for esomeprazole magnesium | 乐普药业股份有限公司 | 2016-08-10 | — | — | CN | claimed |
| US-7227024-B2 | Method for the synthesis of a benzimidazole compound | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | claimed |
| US-20060084811-A1 | Method for the synthesis of a benzimidazole compound | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | US | claimed |
| EP-1556370-A1 | METHOD FOR THE SYNTHESIS OF A BENZIMIDAZOLE COMPOUND | AstraZeneca AB (SE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004035565-A1 | METHOD FOR THE SYNTHESIS OF A BENZIMIDAZOLE COMPOUND | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | WO | claimed |
| WO-2000027841-A1 | METHOD OF PREPARING SULFIDE DERIVATIVES | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2000-05-18 | — | — | WO | claimed |
| EP-0868423-A1 | METHOD FOR THE SYNTHESIS OF A BENZIMIDAZOLE COMPOUND | Astra Aktiebolag (SE) | 1998-10-07 | — | — | EP | claimed |
| WO-1997022603-A1 | METHOD FOR THE SYNTHESIS OF A BENZIMIDAZOLE COMPOUND | ASTRA AKTIEBOLAG (SE) | 1997-06-26 | — | — | WO | claimed |
| EP-0369208-B1 | PROCESS FOR THE PREPARATION OF 3,5-DIMETHYL-4-METHOXY PYRIDINE DERIVATIVES, AND INTERMEDIATE THEREFOR | Hafslund Nycomed Pharma Aktiengesellschaft (AT) | 1993-03-17 | — | — | EP | claimed |
| EP-0240158-B1 | BENZIMIDAZOLE DERIVATIVES | TOKYO TANABE COMPANY LIMITED (JP) | 1991-04-03 | — | — | EP | claimed |
| EP-0369208-A1 | Process for the preparation of 3,5-dimethyl-4-methoxy pyridine derivatives, and intermediate therefor | Hafslund Nycomed Pharma Aktiengesellschaft (AT) | 1990-05-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084811-A1 | Method for the synthesis of a benzimidazole compound | CYP2E1, CYP3A4, CYP3A7 | AGXT 2450/4885HSP90AA1 2906/4885TRAP1 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.